WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of POZEN INC (POZN)

Name POZEN INC
Year low 2.15
Year High 6.39
Symbol POZN
Last trade 4.74
Percentage change 4.18
Volume 145,884
Media Volume (3m) 196,653
PE Ratio N/A
EPS -0.023
Market Cap 141
Media fatt 18
Trend fatt trend fatt graph for POZEN INC
Media net income -25
Trend net income trend net income for POZEN INC
P / E P / E graph for POZEN INC - 0 points 0
EPS EPS graph for POZEN INC - 3 points 3
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for POZEN INC - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for POZEN INC - 7 points 7
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for POZEN INC - 4 points 4
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for POZEN INC - 0 points 0
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for POZEN INC - 0 points 0
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for POZEN INC - 6 points 6
NET INC1/NET INC3 net inc1/net inc3 graph for POZEN INC - 1 points 1
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for POZEN INC - 3 points 3
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for POZEN INC - 3 points 3
. . graph for POZEN INC -  points
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for POZEN INC - 4 points 4
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for POZEN INC - 0 points 0
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for POZEN INC - 1 points 1
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for POZEN INC - 3 points 3
. . graph for POZEN INC -  points
SELL HOLD BUY SELL           HOLD          BUY graph for POZEN INC - 0 points 0
SINTESE 35

GRAPHS

max price logarithm graph for POZEN INC based on no conditions max volume linear graph for POZEN INC based on no conditions

News

POZEN`s Digital Advisory Board to Speak at Annual ePharma Summit (Feb 02 - reuters) Preventive Aspirin Use Less Than Optimal in Stroke Survivors Despite Clinical Guidelines (Feb 02 - reuters) Q&A Exclusive: POZEN's Team Confident About Building Shareholder Value in 2012 and Beyond (Jan 11 - reuters) 6 Great Stocks To Buy Now For Profits In 2012 (Dec 30 - reuters) Twelve Biotech Picks For 2012 (Dec 23 - reuters) Pozen Has No Debt And Plenty Of Resources For 2012 NDA Filing (Nov 29 - reuters) Pozen Deal Unlocks Value (Nov 29 - reuters) UPDATE 1-Pozen now forecasts profit for 2011 (Nov 28 - reuters) 5 of Last Week's Biggest Winners (Nov 28 - reuters) POZEN Monetizes Its Treximet Royalty Stream for $75 Million (Nov 28 - reuters) REFILE-UPDATE 1-Pozen sells migraine drug's U.S. rights to Canada fund (Nov 24 - reuters) POZEN to Present at the Piper Jaffray 23rd Annual Healthcare Conference (Nov 24 - reuters) Positive Results from POZEN Phase 1 Study ("Co-Rx") Presented At AHA (Nov 24 - reuters) Pozen to Present at the Lazard Capital Markets` 8th Annual Healthcare Conference (Nov 24 - reuters) POZEN Reports Third Quarter 2011 Results (Nov 24 - reuters) POZEN To Participate in the Brean Murray Carret & Co. 2011 Life Sciences Summit (Nov 24 - reuters) POZEN Reports Top-Line Data from Long-Term Safety Study of PA32540 (Nov 24 - reuters) POZEN Announces November 3, 2011 Webcast of Third Quarter 2011 Results (Nov 24 - reuters) UPDATE 1-Pozen gives 2011 outlook below Street (Oct 04 - reuters) POZEN Provides Patent Litigation and Financial Guidance Update (Oct 04 - reuters) POZEN Announces Engaging Keelin Reeds Partners LLC to Assist With PA32540 Strategic Partner Search (Oct 03 - reuters) POZEN Announces October 4, 2011 Mid-Quarter Update and Financial Guidance Webcast (Sep 27 - reuters) POZEN To Present at the 2011 UBS Global Life Sciences Conference (Sep 08 - businesswire) POZEN To Present at the 2011 UBS Global Life Sciences Conference (Sep 08 - reuters) POZEN to Present at the 2011 Stifel Nicolaus Healthcare Conference (Aug 24 - businesswire) POZEN to Present at the 2011 Stifel Nicolaus Healthcare Conference (Aug 24 - reuters) POZEN Welcomes Clint Burrus as Vice President, Customer Development (Aug 16 - businesswire) POZEN Welcomes Clint Burrus as Vice President, Customer Development (Aug 16 - reuters) Pozen Patents Upheld in Treximet Patent Litigation (Aug 08 - reuters) UPDATE 1-Pozen's migraine drug patents upheld in litigation (Aug 08 - reuters) Pozen Patents Upheld in Treximet Patent Litigation (Aug 08 - businesswire) POZEN Reports Second Quarter 2011 Results (Jul 28 - businesswire) POZEN Reports Second Quarter 2011 Results (Jul 28 - reuters) POZEN Welcomes Dr. Seth A. Rudnick to the Board of Directors (Jul 27 - businesswire) POZEN Welcomes Dr. Seth A. Rudnick to the Board of Directors (Jul 27 - reuters) POZEN Forms Unprecedented Advisory Board of Digital Thought-Leaders to Advance Commercial Plans (Jul 19 - businesswire) POZEN Forms Unprecedented Advisory Board of Digital Thought-Leaders to Advance Commercial Plans (Jul 19 - reuters) » More POZN.W Market Views (Jul 15 - reuters) » More POZN.A Market Views (Jul 15 - reuters) 11 High-Growth Small Caps With Bullish Short Trends (Jul 14 - reuters) POZEN Announces July 28, 2011 Webcast of Second Quarter 2011 Results (Jul 14 - businesswire) POZEN Announces July 28, 2011 Webcast of Second Quarter 2011 Results (Jul 14 - reuters) POZEN Announces Tomas S. Bocanegra, M.D. as Head of Development (Jul 12 - businesswire) POZEN Announces Tomas S. Bocanegra, M.D. as Head of Development (Jul 12 - reuters) UPDATE 1-Pozen, AstraZeneca's pain drug gets generic threat from Lupin (Jun 16 - reuters) POZEN Announces Election of Dr. Martin Nicklasson to the Board of Directors (Jun 16 - reuters) POZEN Announces Election of Dr. Martin Nicklasson to the Board of Directors (Jun 16 - businesswire) POZEN to Present at The UBS Specialty Pharmaceuticals Conference (Jun 15 - businesswire) POZEN to Present at The UBS Specialty Pharmaceuticals Conference (Jun 15 - reuters) POZEN to Present at the 2011 Wells Fargo Securities Healthcare Conference (Jun 09 - businesswire)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY